IMPACT OF INHIBITION OF PCSK-9 AMONG RENAL TRANSPLANT RECIPIENTS WITH HIGH CARDIOVASCULAR RISK

被引：0
|
作者：
Alotaibi, Torki [1 ]
Gheith, Osama Ashry Ahmed [1 ,2 ]
Nagib, Ayman Maher [1 ,2 ]
Aboatya, Hasaneen Hasaneen Ahmed Aboatya [1 ]
Halim, Medhat M. A. [1 ]
Mahmoud, Tarek S. H. [1 ]
Emam, Mohamed [1 ]
Mostafa, Mohamed [1 ]
Elsayed, Zakaria [1 ]
Nair, Prasad [1 ]
机构：
[1] OTC Kuwait, Kuwait, Kuwait
[2] Mansoura Univ, Nephrol, Mansoura, Egypt
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO972
引用
收藏
页码：I706 / I706
页数：1
相关论文
共 50 条
  • [1] IMPACT OF INHIBITION OF PCSK-9 AMONG RENAL TRANSPLANT RECIPIENTS WITH HIGH CARDIOVASCULAR RISK
    Gheith, Osama
    Elotaibi, Torki
    Abo-Atteya, Hasaneen
    Najeeb, Ayman M.
    Saed, Tarek
    Halim, Medhat A.
    Balha, Mohamed
    Abdul-Tawaab, Khalid
    Abdul-Hameed, Mohamed
    Elserwy, Nabil
    Sami, Ahmed
    Nair, Prasad
    TRANSPLANT INTERNATIONAL, 2019, 32 : 397 - 397
  • [2] IMPACT OF INHIBITION OF PCSK-9 AMONG RENAL TRANSPLANT RECIPIENTS WITH HIGH CARDIOVASCULAR RISK
    Gheith, O. A.
    Alotaibi, T.
    Aboatteya, H.
    Nagib, A.
    Halim, M. A.
    Said, T.
    Abdelhameed, M.
    Elserwy, N.
    Sami, A.
    Nair, P.
    ATHEROSCLEROSIS, 2020, 315 : E281 - E281
  • [3] IMPACT OF INHIBITION OF PCSK-9 AMONG RENAL TRANSPLANT RECIPIENTS WITH HIGH CARDIOVASCULAR RISK
    Gheith, Osama
    Alotaibi, Torki
    Nagib, Ayman Maher
    Aboatya, Hasaneen
    Halim, Medhat A.
    Mahmoud, Tarek
    Emam, Mohamed
    Elsayed, Zakaria
    Nair, Prasad
    TRANSPLANT INTERNATIONAL, 2021, 34 : 118 - 118
  • [4] Inhibition of Proprotein Convertase Subtilisin/Kexin Type A (PCSK-9) Among Renal Transplant Recipients: Is It Beneficial For Cases With High Cardiovascular Risk?
    Al-Otaibi, Torki
    Gheith, Osama
    Nagib, Ayman M.
    Aboatya, Hasaneen
    Halim, Medhat A.
    Said, Tarek
    Emam, Mohamed
    El-Sayed, Zakaria
    Nair, Prasad
    TRANSPLANTATION, 2022, 106 (09) : S374 - S374
  • [5] PCSK-9: Entering a new era of cardiovascular risk prediction
    Schindler, Thomas H.
    Leucker, Thorsten M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 263 : 152 - 153
  • [6] Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention
    Robinson, Jennifer G.
    Heistad, Donald D.
    Fox, Keith A. A.
    ATHEROSCLEROSIS, 2015, 243 (02) : 593 - 597
  • [7] Effect of mTORS vs CNI on Lipid Levels in Renal Transplant Recipients and the Role of the PCSK-9 Inhibitors in Lipid Management
    Martinez-Yamada, S.
    Anumolu, R.
    Pandav, J.
    Saranu, R.
    Vela, X.
    Safa, K.
    Aala, A.
    Muhsin, S.
    Gabardi, S.
    Chandraker, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S561 - S561
  • [8] Evolution and Impact of Cardiovascular Risk Factors in Renal Transplant Recipients
    Freguin, C.
    Benard, L.
    Le Roy, F.
    Hanoy, M.
    Bertrand, D.
    Guerrot, D.
    Godin, M.
    Etienne, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 288 - 288
  • [9] Efficacy and Safety of PCSK-9 Inhibitor, Evolocumab for Lipid Management in Kidney Transplant Recipients.
    Pandav, J.
    Saranu, R.
    Muhsin, S.
    Murakami, N.
    Gabardi, S.
    Safa, K.
    Chandraker, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 678 - 678
  • [10] Cardiovascular risk in renal transplant recipients
    Devine, Paul A.
    Courtney, Aisling E.
    Maxwell, Alexander P.
    JOURNAL OF NEPHROLOGY, 2019, 32 (03) : 389 - 399
12345